Table 3.
Clinical response in 17 evaluable patients
No. (%) | Clinical benefit | Median OS (months) | |
---|---|---|---|
PR |
1 (5.8) |
7/17 (41%) |
14 |
SD |
6 (35.2) |
||
PD |
10 (58.8) |
|
6.5 |
All 17 patients | 10 |
PR Partial response, SD Stable disease, PD Progressive disease, OS Overall survival.